Our Healthcare System. Canada’s health and pharmacare programs serve the needs of most Canadians. However, the quality of care and access – especially for those with special needs and those who do not have access to a pharmacare plan – needs to be addressed.
Our Biopharmaceutical Industry. The industry contributes to a strong Canadian economy by employing 13,000 Canadians directly, supporting over 30,000 jobs in total and driving over $19 billion in annual economic activity. With respect to other economic sectors, Life Sciences ranks 3rd in terms of combined total R&D spending in Canada, behind only the Aerospace and Software and Computer Services sectors.
Our Research Ecosystem. It took over thirty years to build Canada’s health research ecosystem. It is strong and growing, but can only continue to do so with a supportive policy environment that encourages growth and investment.
Accessible medicines for all Canadians: A health system that ensures all Canadians get the medicines and vaccines they need no matter their financial situation.
Affordable medicines: Make medicines and vaccines affordable for governments and private insurance companies to support a sustainable and high-quality health system.
Appropriate use of medicines: Promote appropriate use of medicines to ensure better health outcomes and a high-performing and efficient health system.
Investment and innovation: A globally competitive Canadian biopharma research and innovation ecosystem that includes universities, research centres and companies focused on outcomes that matter to patients, the health system and the economy.
Le Conseil d’examen du prix des médicaments brevetés (CEPMB) a été créé en 1987. L’un des mandats du CEPMB est d’assurer que le prix des médicaments brevetés ne soit pas « excessif ». Une des façons d’évaluer le prix « excessif » est de vérifier si le prix du médicament au Canada est dans la médiane parmi sept pays de comparaison.
Un gouvernement ne peut rester riche bien longtemps lorsque sa population ne peut plus conserver sa santé.
Everyone wants affordable medicines, but are Canadians prepared to accept the trade-off of even longer delays before we can access innovative drugs?
Pharmaceutical companies today generally get full control over how their drugs are licensed and priced when making patent deals with publicly funded researchers, but Herder said he’d like to see the scientists bargain a little harder for the right to make decisions that are also in the public interest.
With regards to today's publication of proposed amendments to the Patented Medicines Regulations, Pamela Fralick, President, Innovative Medicines Canada issued a statement.